[go: up one dir, main page]

PE20090311A1 - Proteinas de fusion natriureticas - Google Patents

Proteinas de fusion natriureticas

Info

Publication number
PE20090311A1
PE20090311A1 PE2008000956A PE2008000956A PE20090311A1 PE 20090311 A1 PE20090311 A1 PE 20090311A1 PE 2008000956 A PE2008000956 A PE 2008000956A PE 2008000956 A PE2008000956 A PE 2008000956A PE 20090311 A1 PE20090311 A1 PE 20090311A1
Authority
PE
Peru
Prior art keywords
natriuretic peptide
natriuretic
domain
connector
fusion proteins
Prior art date
Application number
PE2008000956A
Other languages
English (en)
Inventor
Keith Canada
Uwe Schoenbeck
Eugene R Hickey
Adam Mezo
Kevin Mcdonnell
Original Assignee
Boehringer Ingelheim Int
Syntonix Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39717543&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20090311(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int, Syntonix Pharmaceuticals Inc filed Critical Boehringer Ingelheim Int
Publication of PE20090311A1 publication Critical patent/PE20090311A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Oncology (AREA)

Abstract

REFERIDA A UNA PROTEINA DE FUSION QUE COMPRENDE UN PEPTIDO NATRIURETICO DE FORMULA: X-La-F:F-La-X O X-La-F:F, Y UN DOMINIO Fc DE ANTICUERPO, DONDE EL PEPTIDO NATRIURETICO ESTA CONJUGADO CON EL DOMINIO Fc DIRECTAMENTE O A TRAVES DE UN CONECTOR Y DONDE X ES UN PEPTIDO NATRIURETICO, L ES UN CONECTOR QUE COMPRENDE RESIDUOS DE AMINOACIDOS, a ES UN NUMERO ENTERO; : ES UNA ASOCIACION QUIMICA O ENTRECRUZAMIENTO; F ES UNA PARTE DE UN DOMINIO Fc DE IMMUNOGLOBULINA QUE COMPRENDE UN SITIO DE UNION PARA FcRn. EL PEPTIDO NATRIURETICO ES UN PEPTIDO NATRIURETICO TIPO A (ANP) O UN PEPTIDO NATRIURETICO TIPO B (BNP); EL CONECTOR TIENE 6, 11, 16 O 20 AMINOACIDOS DE LONGITUD. TAMBIEN ESTA REFERIDA A UN POLIPEPTIDO. DICHAS PROTEINAS DE FUSION TIENEN ACTIVIDAD DIURETICA, NATRIURETICA Y VASODILATADORA Y SON UTILES EN EL TRATAMIENTO DE INSUFICIENCIA CARDIACA CRONICA, FIBROSIS CARDIACA, ENTRE OTRAS
PE2008000956A 2007-06-06 2008-06-05 Proteinas de fusion natriureticas PE20090311A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US94245507P 2007-06-06 2007-06-06

Publications (1)

Publication Number Publication Date
PE20090311A1 true PE20090311A1 (es) 2009-04-09

Family

ID=39717543

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008000956A PE20090311A1 (es) 2007-06-06 2008-06-05 Proteinas de fusion natriureticas

Country Status (10)

Country Link
US (1) US20100310561A1 (es)
EP (1) EP2162464A1 (es)
JP (1) JP2010530222A (es)
AR (1) AR066885A1 (es)
CA (1) CA2689492A1 (es)
CL (1) CL2008001661A1 (es)
PE (1) PE20090311A1 (es)
TW (1) TW200906849A (es)
UY (1) UY31123A1 (es)
WO (1) WO2008154226A1 (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1759001T3 (da) 2004-04-21 2011-08-01 Enobia Pharma Inc Konjugat til tilførsel til knogler og fremgangsmåde til fremstilling deraf ved at målrette proteiner til knoglen
US20120093814A1 (en) * 2009-03-30 2012-04-19 Boehringer Ingelheim International Gmbh Fusion Proteins Comprising Canine FC Portions
BR122019026832B1 (pt) 2009-05-20 2021-08-24 Biomarin Pharmaceutical Inc Variantes de peptídeo natriurético tipo c (cnp), seu método de produção recombinante e seu uso, composição farmacêutica, composição para tratamento de uma condição ou distúrbio responsivo a cnp e célula hospedeira para produção in vitro de um peptídeo cnp
TW201120210A (en) * 2009-11-05 2011-06-16 Hoffmann La Roche Glycosylated repeat-motif-molecule conjugates
EA201291138A1 (ru) 2010-04-30 2013-05-30 Алексион Фарма Интернэшнл Сарл Способы, композиции и наборы для лечения нарушений, связанных с минерализацией матрикса
US8921516B2 (en) * 2010-12-08 2014-12-30 Corning Incorporated Synthetic, defined fibronectin mimetic peptides and surfaces modified with the same
AU2011350066A1 (en) 2010-12-27 2013-07-11 Alexion Pharma International Sarl Compositions comprising natriuretic peptides and methods of use thereof
CN103402542B (zh) 2011-02-28 2017-05-03 独立行政法人国立循环器病研究中心 恶性肿瘤转移抑制用药物
WO2013027680A1 (ja) 2011-08-19 2013-02-28 独立行政法人国立循環器病研究センター ナトリウム利尿ペプチド受容体gc-aアゴニスト及びgc-bアゴニストを組み合わせてなる悪性腫瘍の増悪防止用医薬
SG11201401605QA (en) 2011-10-19 2014-09-26 Alexion Pharma Holding Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
TW201442721A (zh) 2013-01-23 2014-11-16 Daiichi Sankyo Co Ltd 糖鏈修飾心房利尿鈉肽
EP3116486B1 (en) * 2014-03-14 2019-12-04 Daniel J. Capon Hybrid immunoglobulin containing non-peptidyl linkage
TWI593967B (zh) * 2014-05-01 2017-08-01 高雄醫學大學 二級抗體所辨識之抗原決定位及其用途
US10822596B2 (en) 2014-07-11 2020-11-03 Alexion Pharmaceuticals, Inc. Compositions and methods for treating craniosynostosis
CA2967851C (en) 2014-12-05 2024-02-27 Alexion Pharmaceuticals, Inc. Treating seizure with recombinant alkaline phosphatase
JP6868561B2 (ja) 2015-01-28 2021-05-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼ欠損を有する被験者を治療する方法
CN104861075B (zh) * 2015-05-08 2018-06-08 成都金凯生物技术有限公司 一种长效重组人脑钠肽融合蛋白及其制备方法与用途
AU2016308624B2 (en) 2015-08-17 2022-06-23 Alexion Pharmaceuticals, Inc. Manufacturing of alkaline phosphatases
US11229686B2 (en) 2015-09-28 2022-01-25 Alexion Pharmaceuticals, Inc. Reduced frequency dosage regimens for tissue non-specific alkaline phosphatase (TNSALP)-enzyme replacement therapy of hypophosphatasia
JP2018533571A (ja) 2015-10-30 2018-11-15 アレクシオン ファーマシューティカルズ， インコーポレイテッド 患者の頭蓋縫合早期癒合症を治療するための方法
US11065306B2 (en) 2016-03-08 2021-07-20 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children
EP3436020A4 (en) 2016-04-01 2019-12-25 Alexion Pharmaceuticals, Inc. METHOD FOR TREATING HYPOPHOSPHATASIE IN TEENS AND ADULTS
US11186832B2 (en) 2016-04-01 2021-11-30 Alexion Pharmaceuticals, Inc. Treating muscle weakness with alkaline phosphatases
US10988744B2 (en) 2016-06-06 2021-04-27 Alexion Pharmaceuticals, Inc. Method of producing alkaline phosphatase
EP4159749A3 (en) 2016-07-01 2023-06-14 Daiichi Sankyo Company, Limited A method for producing fc-containing molecule with remodeled sugar chain
WO2018035420A1 (en) 2016-08-18 2018-02-22 Alexion Pharmaceuticals, Inc. Methods for treating tracheobronchomalacia
MY201165A (en) * 2017-03-22 2024-02-08 Pharmain Corp Npra agonists, compositions, and uses thereof
KR20240158374A (ko) 2017-03-31 2024-11-04 알렉시온 파마슈티칼스, 인코포레이티드 성인 및 청소년에서 저포스파타제증 (hpp)을 치료하는 방법
JP2021519590A (ja) 2018-03-30 2021-08-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド 糖タンパク質の製造
EP3553081A1 (en) 2018-04-12 2019-10-16 Bayer Aktiengesellschaft Atrial natriuretic peptide engrafted antibodies
EP3553082A1 (en) 2018-04-12 2019-10-16 Bayer Aktiengesellschaft Brain natriuretic peptide engrafted antibodies
EP3553079A1 (en) 2018-04-12 2019-10-16 Bayer Aktiengesellschaft C-type natriuretic peptide engrafted antibodies
WO2020033867A2 (en) 2018-08-10 2020-02-13 Alexion Pharmaceuticals, Inc. Methods of treating neurofibromatosis type 1 and related conditions with alkaline phosphatase
CN112805303B (zh) * 2018-10-23 2024-08-20 瑞泽恩制药公司 抗npr1抗体及其用途
CN110964098B (zh) * 2019-10-23 2022-10-04 武汉奥科博泰生物科技有限公司 一种n端脑钠肽变体蛋白及其制备方法和应用
CA3161266A1 (en) 2019-12-09 2021-06-17 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof
AU2021401415A1 (en) 2020-12-18 2023-07-13 Regeneron Pharmaceuticals, Inc. Immunoglobulin proteins that bind to npr1 agonists
US12083169B2 (en) 2021-02-12 2024-09-10 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof
AU2023364177A1 (en) 2022-10-21 2025-05-01 Eli Lilly And Company Long-acting natriuretic peptides and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2488348A1 (en) * 2002-07-31 2004-02-05 Conjuchem Inc. Long lasting natriuretic peptide derivatives
US20050176108A1 (en) * 2003-03-13 2005-08-11 Young-Min Kim Physiologically active polypeptide conjugate having prolonged in vivo half-life
WO2005007809A2 (en) * 2003-05-30 2005-01-27 Alexion Pharmaceuticals, Inc. Antibodies and fusion proteins that include engineered constant regions
RU2352583C2 (ru) * 2003-11-13 2009-04-20 Ханми Фарм. Инд. Ко., Лтд. ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ Fc-ОБЛАСТЬ ИММУНОГЛОБУЛИНА В КАЧЕСТВЕ НОСИТЕЛЯ
KR100754667B1 (ko) * 2005-04-08 2007-09-03 한미약품 주식회사 비펩타이드성 중합체로 개질된 면역글로불린 Ｆｃ 단편 및이를 포함하는 약제학적 조성물
CA2625600A1 (en) * 2005-10-14 2007-04-26 Biorexis Pharmaceutical Corporation Natriuretic peptide modified transferrin fusion proteins
US8008257B2 (en) * 2005-10-20 2011-08-30 University Of Ottawa Heart Institute ANF fusion proteins
US20080181903A1 (en) * 2006-12-21 2008-07-31 Pdl Biopharma, Inc. Conjugate of natriuretic peptide and antibody constant region

Also Published As

Publication number Publication date
WO2008154226A1 (en) 2008-12-18
TW200906849A (en) 2009-02-16
CA2689492A1 (en) 2008-12-18
JP2010530222A (ja) 2010-09-09
AR066885A1 (es) 2009-09-16
CL2008001661A1 (es) 2009-03-20
UY31123A1 (es) 2008-11-28
EP2162464A1 (en) 2010-03-17
US20100310561A1 (en) 2010-12-09

Similar Documents

Publication Publication Date Title
PE20090311A1 (es) Proteinas de fusion natriureticas
Karas et al. 2‐Nitroveratryl as a photocleavable thiol‐protecting group for directed disulfide bond formation in the chemical synthesis of insulin
ES2523898T3 (es) Regiones de escisión KEX2 de proteínas de fusión recombinantes
HRP20200007T1 (hr) Kompleks proteina faktora viii s xten i von willebrandovim faktorom, te njegova uporaba
ATE517120T1 (de) Igf-1 fusion polypeptide und deren therapeutische verwendung
CL2012000063A1 (es) Polipéptido factor ix (fix) o un fragmento del mismo porque comprende la modificación de un aminoácido; vector; célula; método para expresar el polipéptido fix; composición farmacéutica; uso de la composición para tratar enfermedades trombóticas, hemorrágicas y coagulación intravascular diseminada (cid) (div. sol. 1796-07).
ATE522563T1 (de) Verzweigte polyalkylenglykole
EP2298331A3 (en) Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
ATE546533T1 (de) Rekombinante expression von proteinen in einer disulfidverbrückten, zweikettigen form
PE20130205A1 (es) Proteinas de union a il-1
PE20090225A1 (es) Proteinas de fusion que degradan el peptido beta amiloide
HN2009001593A (es) Coagnistas de receptor de glucagon/glp-1
AR080914A1 (es) Proteinas de union al beta-amiloide
AR076977A1 (es) Proteinas precursoras repetitivas autoensambladas
DE10342794A1 (de) Sekretion von Proteinen aus Hefen
NO20063026L (no) Antistoffer
PE20181890A1 (es) Contorsbody - un ligante de diana monocatenario
AR036384A1 (es) Una proteina de fusion que tiene actividad de eritropoyetina in vivo aumentada
AR067980A1 (es) Peptidos de cdh3 y agentes que los comprenden
MX2022003531A (es) Polipeptidos de fusion dap10/dap12.
BR112018073669A2 (pt) proteína de fusão, composição de uma primeira proteína e uma segunda proteína, complexo de uma primeira proteína e uma segunda proteína, polinucleotídeos que codificam uma proteína de fusão, vetor contendo o polinucleotídeo, célula hospedeira contendo o polinucleotídeo, uso de uma proteína de fusão, composição farmacêutica, e composição farmacêutica para uso
MX2017010359A (es) Cadena alfa del receptor de inmunoglobulina e (ige) de alta afinidad de fusion de fragmento cristalizable (fc).
ME02653B (me) Genski proizvodi koji su diferencijalno izraženi u tumorima i njihova primjena
WO2007018619A3 (en) Chimeric therapeutic agents
JP2019535645A5 (es)

Legal Events

Date Code Title Description
FD Application declared void or lapsed